Other notable genomic biomarkers include anaplastic lymphoma kinase (ALK) rearrangements and ROS1 fusions, both of which are also linked to targeted therapy responsiveness in NSCLC (42, 43). The gene discussed is ALK; the disease is non-small cell lung carcinoma.